It's early days for xenotransplantation, but eGenesis, Eledon, United Therapeutics and more are working to develop solutions ...

Dr. Shivaani Kummar is stepping into the role of OHSU Knight Cancer Institute chief executive on an interim basis, OHSU ...

Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round Novo Holdings and Jeito Capital co-led the deal, supported by Asabys Partners and existing investo ...

said Samira Sakhia, President and CEO of Knight. Minjuvi ® (tafasitamab ... Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics ...

President & CEO of Arcturus Therapeutics. "Arcturus continues to make excellent progress with our STARR® sa-mRNA vaccines pipeline and platform. We are very pleased to have recently received ...

Evofem will maintain ownership of the asset and continue to commercialize PHEXXI in the United States and internationally ... U.S.,” said Saundra Pelletier, CEO of Evofem.

and I believe this transaction will maximize value for our stockholders and provide accelerated access to Unloxcyt in the United States, Europe, and other markets worldwide." 1. Sun Pharma to Acquire ...

Multinational pharmaceutical firms, particularly U.S. giants, are increasingly recognizing China's burgeoning innovative drug sector as a strategic goldmine to bolster their global competitiveness.

Heron Therapeutics' market cap has risen to ~$360 ... In response to a question about Heron's expectations about VAN's impact CEO Collard advised: ...what we're seeing is the reception so far ...

The global CAR T-cell therapy market is projected to grow from USD 2.7 billion in 2025 to over USD 27.5 billion by 2033, reflecting a robust CAGR of 26.2%.